| 2026-08-05 | Press release | Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference |
| 2026-08-04 | Press release | Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-04 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-30 | Press release | Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop o |
| 2026-07-28 | Press release | Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 20 |
| 2026-07-14 | Deck | First-in-disease therapies for patients with rare diseases Corporate Presentation |
| 2026-07-14 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-30 | Press release | Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors |
| 2026-06-30 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-29 | Press release | Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations |
| 2026-06-22 | Press release | FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations |
| 2026-06-16 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-03 | Press release | Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations |
| 2026-06-02 | Press release | Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 |
| 2026-05-27 | Press release | Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 |
| 2026-05-20 | Deck | Investor presentation · May 2026 |
| 2026-05-20 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-15 | Press release | Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology |
| 2026-05-15 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-13 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Press release | Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas |
| 2026-04-30 | Proxy | Definitive proxy statement |
| 2026-04-20 | Press release | Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 |
| 2026-04-13 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-07 | 8-K | Form 8-K, Item 8.01 |
| 2026-03-31 | Press release | Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update |
| 2026-03-31 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-31 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-27 | Press release | Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting |
| 2026-03-24 | Press release | Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 |
| 2026-02-26 | 8-K | Form 8-K, Item 1.01 |
| 2026-02-24 | Deck | First-in-disease therapies for patients with rare diseases Phase 3 SELVA Topline Data in Microcystic Lymphatic Malformations · Q1 2026 |
| 2026-02-24 | Press release | Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations |
| 2026-02-24 | 8-K | Form 8-K, Item 8.01 |
| 2026-02-24 | 8-K | Form 8-K, Item 7.01 |
| 2026-02-24 | 8-K | Form 8-K, Item 2.02 results |